Should anti-CD20 be used as an immune reconstitution therapy?

Ide Smets; Beatrijs Wokke; Joost Smolders

doi:10.1177/13524585221109386

Should anti-CD20 be used as an immune reconstitution therapy?

Ide Smets^*
, Beatrijs Wokke
, Joost Smolders

^*Corresponding author for this work

Netherlands Institute for Neuroscience

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

7 Citations (Scopus)

58 Downloads (Pure)

Original language	English
Pages (from-to)	308-310
Number of pages	3
Journal	Multiple Sclerosis Journal
Volume	29
Issue number	2
Early online date	13 Jul 2022
DOIs	https://doi.org/10.1177/13524585221109386
Publication status	Published - Feb 2023

Bibliographical note

Access to Document

10.1177/13524585221109386Licence: CC BY-NC

13524585221109386Final published version, 155 KBLicence: CC BY-NC

Cite this

@article{44640ce4696c40c493735df934ea02ce,

title = "Should anti-CD20 be used as an immune reconstitution therapy?",

author = "Ide Smets and Beatrijs Wokke and Joost Smolders",

note = "{\textcopyright} The Author(s), 2022. ",

year = "2023",

month = feb,

doi = "10.1177/13524585221109386",

language = "English",

volume = "29",

pages = "308--310",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",